Natural Capsules Ltd

AI
Natural Capsules Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Natural Capsules Ltd

₹ 152 0.32%
21 Aug - close price
naturalcapsules.com BSE: 524654 NSE: NATCAPSUQ
About

Incorporated in 1993, Natural Capsules manufactures Capsules and Steroidal APIs and their Intermediates and Derivatives[1]

Key Points

Business Overview:[1][2][3]
NCL is a WHO-GMP certified and ISO 9001, ISO 140001 compliance manufacturer of printed and unprinted hard two-piece Gelatin and Cellulose (HPMC : non-animal alternative) capsules for pharmaceutical and dietary supplement industries in various sizes. Apart from this, NCL has forayed into API manufacturing with complex high-end patented technology developed in-house, under its subsidiary company **Natural Biogenex Private Limited. **

Website BSE NSE
  • Market Cap ₹ 158 Cr.
  • Current Price ₹ 152
  • High / Low ₹ 296 / 136
  • Stock P/E
  • Book Value ₹ 168
  • Dividend Yield 0.00 %
  • ROCE -4.58 %
  • ROE -9.45 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Stock is trading at 0.90 times its book value

Cons

  • Company has low interest coverage ratio.
  • Company has a low return on equity of -2.06% over last 3 years.
  • Contingent liabilities of Rs.75.2 Cr.
  • Company might be capitalizing the interest cost
  • Earnings include an other income of Rs.3.72 Cr.
  • Promoter holding has decreased over last 3 years: -5.65%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
37.70 37.52 39.98 40.22 39.18 41.22 43.83 44.97 45.20 45.80 37.75 58.45 48.71
31.74 32.40 35.26 36.11 34.81 36.72 39.56 40.58 44.88 46.69 40.07 57.12 47.59
Operating Profit 5.96 5.12 4.72 4.11 4.37 4.50 4.27 4.39 0.32 -0.89 -2.32 1.33 1.12
OPM % 15.81% 13.65% 11.81% 10.22% 11.15% 10.92% 9.74% 9.76% 0.71% -1.94% -6.15% 2.28% 2.30%
0.17 0.35 0.50 0.92 0.18 0.11 0.11 0.30 0.36 0.16 0.45 0.76 2.35
Interest 1.33 1.16 1.24 1.40 1.49 1.65 1.54 1.64 2.53 2.68 2.85 2.89 4.97
Depreciation 2.11 2.17 2.19 2.20 2.28 2.35 2.33 2.16 4.21 4.29 4.36 4.28 4.33
Profit before tax 2.69 2.14 1.79 1.43 0.78 0.61 0.51 0.89 -6.06 -7.70 -9.08 -5.08 -5.83
Tax % 32.34% 27.10% 32.96% 32.17% 21.79% 201.64% 78.43% 41.57% -8.09% -9.09% -21.70% -1.97% -1.54%
1.82 1.56 1.21 0.97 0.60 -0.61 0.11 0.52 -5.58 -6.99 -7.12 -4.98 -5.75
EPS in Rs 1.96 1.68 1.30 1.04 0.64 -0.60 0.11 0.35 -5.40 -6.76 -4.77 -3.32 -3.82
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
55 60 62 80 135 170 155 169 187 191
49 55 56 68 110 135 135 151 188 191
Operating Profit 6 5 5 11 26 35 20 18 -1 -1
OPM % 10% 8% 9% 14% 19% 21% 13% 10% -0.5% -0.4%
1 1 1 3 1 1 2 1 2 4
Interest 0 1 1 1 2 4 5 7 12 13
Depreciation 4 3 4 4 5 7 9 9 17 17
Profit before tax 2 2 1 9 19 25 8 3 -28 -28
Tax % 34% 7% 38% 24% 28% 26% 31% 78% -12%
1 2 1 7 14 18 6 1 -25 -25
EPS in Rs 1.19 2.06 0.92 7.43 14.96 20.02 5.95 0.42 -16.44 -18.67
Dividend Payout % 56% 32% 43% 9% 5% 5% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 19%
3 Years: 3%
TTM: 9%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -238%
Stock Price CAGR
10 Years: 8%
5 Years: 2%
3 Years: -27%
1 Year: -23%
Return on Equity
10 Years: %
5 Years: 3%
3 Years: -2%
Last Year: -9%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 6 6 6 6 7 9 9 10 10
Reserves 48 49 49 56 76 114 194 176 165
0 5 6 10 53 97 109 152 162
19 14 14 27 29 70 64 81 87
Total Liabilities 73 75 76 99 165 290 377 419 424
22 24 24 38 66 97 103 284 274
CWIP 1 2 2 7 20 88 144 0 4
Investments 5 5 6 0 0 0 3 3 3
45 43 45 54 79 105 127 133 143
Total Assets 73 75 76 99 165 290 377 419 424

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
5 2 7 13 -1 17 -8 27 11
-1 -7 -6 -16 -46 -105 -73 -44 -11
-4 4 -1 3 48 87 82 16 -1
Net Cash Flow 0 -1 0 -0 1 0 1 -2 -0
Free Cash Flow 4 -5 2 -11 -47 -88 -79 -18 -1
CFO/OP 97% 57% 144% 134% 17% 64% -32% 162% -1,634%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 208 197 180 123 71 112 128 134 139
Inventory Days 149 87 89 82 34 45 88 109 94
Days Payable 185 114 91 159 98 127 141 166 197
Cash Conversion Cycle 172 170 179 45 7 30 75 78 36
Working Capital Days 186 143 121 35 73 61 80 53 -1
ROCE % 5% 4% 11% 21% 15% 5% 3% -5%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Capsules Capacity Utilization
%

Log in to view insights

Please log in to see hidden values.

Login
Capsules Installed Capacity
BCPA (Billion Capsules Per Annum)
Export Revenue Share
%
Number of Countries Exported To
count
Number of Customers
count
R&D Team Size
count
HPMC Capsule Lines (New Generation)
count
Repeat Business Share
%
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

1 Recently
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
56.57% 56.57% 56.57% 56.57% 51.59% 51.13% 51.21% 51.26% 51.26% 51.26% 51.04% 50.92%
1.31% 1.31% 1.31% 0.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
42.13% 42.13% 42.13% 43.25% 48.39% 48.86% 48.80% 48.75% 48.73% 48.74% 48.96% 49.09%
No. of Shareholders 11,67511,39910,95410,5149,8629,6619,4259,3119,5739,0758,8508,756

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls